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ffects of Gender on Peak
xygen Consumption and the
iming of Cardiac Transplantation
ammy Elmariah, MD,* Lee R. Goldberg, MD, MPH, FACC,* Michael T. Allen, EMT-P,*
ndrew Kao, MD, FACC†
hiladelphia, Pennsylvania; and Kansas City, Missouri
OBJECTIVES This study examines the gender effects on peak exercise oxygen consumption (VO2) and
survival in heart failure (HF) patients and their implications for cardiac transplantation.
BACKGROUND The predictive value of peak VO2 in women HF patients is poorly established but is one of
the indicators used to optimally time cardiac transplantation in women.
METHODS A total of 594 ambulatory HF patients (mean age 52  12 years, 28% women, mean left
ventricular ejection fraction 26  12%, 73% on beta-blocker) underwent symptom-limited
exercise tests with breath-by-breath expired gas analyses using ramped treadmill protocols.
Kaplan-Meier survival curves were generated for each gender and compared using log-rank tests.
RESULTS Women had a significantly lower peak VO2 than men (14.0  4.9 ml/kg/min vs. 16.6  7.1
ml/kg/min; p  0.0001), despite being younger (48.9  11.5 years vs. 53.2  12.4 years;
p  0.0001) and having a higher left ventricular ejection fraction (29  13% vs. 25  11%;
p  0.0003). However, the one-year transplant-free survival was significantly lower for men
than for women (81% vs. 94%, p  0.0001), a finding seen across each Weber class. Cox
regression analyses confirmed the protective effects of female gender on transplant-free
survival when controlling for peak VO2, age, race, beta-blocker use, and type of cardiomy-
opathy. The peak VO2 associated with 85% one-year transplant-free survival was significantly
higher in men than in women (11.5 vs. 10.0 ml/kg/min).
CONCLUSIONS Women had a significantly lower peak VO2 than men, but had better survival at all levels of
exercise capacity. The current practice of uniform application of peak VO2 as an aid to
determine cardiac transplantation timing should be re-examined. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.08947:2237–42) © 2006 by the American College of Cardiology Foundation
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teak oxygen consumption (VO2) is a reliable predictor of
urvival in patients with advanced heart failure (HF) (1–7).
onsequently, peak VO2 is used for determining the timing
f cardiac transplantation (3–7). Mancini et al. (3) showed
hat patients with a peak VO2 14 ml/kg/min had poor
utcomes and benefit from cardiac transplantation. How-
ver, this and other major studies examining the use of peak
O2 as a predictor of outcomes in HF evaluated few women
3–7). As peak VO2 is influenced by age, gender, muscle mass,
otivation, and pulmonary status (8,9), it is unclear whether
eak VO2 values provide the same prognostic information in
omen.
See page 2243
Despite their under-representation in HF trials, women
onstitute a significant proportion of cardiac transplant
ecipients in the U.S. United Network for Organ Sharing
ata reveal that in 2003, 26% of cardiac transplant recipients
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005, accepted November 28, 2005.ere women. Because peak VO2 has not been validated in
emale HF patients, it is possible that its use in evaluating
omen leads to premature cardiac transplantation. Because
here is a relative shortage of donor organs (10) and
ost-transplantation survival is limited, it is of the utmost
mportance that organs are allocated as appropriately as
ossible.
Given several gender-based differences in the pathophys-
ology and progression of HF (11–15), it is apparent that
F management, including the application of peak VO2,
hould be customized for the patient population being
reated (5–9,16–18). Here we describe a large and diverse
opulation of ambulatory HF patients and their perfor-
ance on cardiopulmonary exercise testing to delineate the
rognostic value of peak VO2 in women patients.
ETHODS
atient population. A total of 726 patients underwent
,028 cardiopulmonary exercise tests between July 2000 and
ecember 2003 at the University of Pennsylvania’s Heart
ailure and Transplant Ambulatory Care Center to evaluate
unctional capacity, HF management, and transplantation
iming. Patient demographics, co-existing conditions, and
edications were prospectively recorded before each test;
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Effects of Gender on Peak VO2 June 6, 2006:2237–42hereas left ventricular ejection fraction (LVEF) and pa-
ient outcomes were retrospectively determined from med-
cal records.
Patients were included in this analysis if they had a LVEF
45% as measured by echocardiography, left ventriculo-
ram, or nuclear imaging. For patients with multiple VO2
ests during the study period, only the first test was used for
nalysis.
End points for this study were death and orthotopic heart
ransplantation (OHT) from the date of study until June 30,
004. Whenever possible, the date of patient death, as
ocumented in patient records or in the Social Security
eath Index, was used. However, in the event that the exact
ate of death was unknown, the midpoint between the date
f last contact and the date when the death was reported was
Table 1. Baseline Patient Characteristics of M
Characteristics
Overall, n (%
(n  594)
Age (yrs) 52  12
LVEF (%) 26  12
Body mass index 29  5
Race
White 453 (76)
Black 127 (21)
Hispanic 7 (1)
Asian 7 (1)
Etiology of HF
Idiopathic 319 (54)
Ischemic 206 (35)
Valvular 28 (5)
Other 41 (7)
Therapies
Beta-blockers 431 (73)
ACE inhibitors 455 (77)
ARBs 97 (16)
Aspirin 241 (41)
Calcium channel blockers 35 (6)
Digoxin 421 (71)
Diuretics 424 (72)
Spironolactone 60 (10)
Lipid-lowering medications 171 (29)
Nitrates 53 (9)
ICD 77 (13)
Comorbidities
Hypertension 195 (33)
Diabetes 137 (23)
Lung disease (asthma/COPD) 41 (7)
Atrial fibrillation 68 (11)
Plus-minus values are mean  standard deviation. NS  p
Abbreviations and Acronyms
HF  heart failure
LVEF  left ventricular ejection fraction
OHT  orthotopic heart transplant
RER  respiratory exchange ratio
VO2  oxygen consumptionACE  angiotensin-converting enzyme; ARBs  angiotensin II
disease; HF  heart failure; ICD  implantable cardioverter-defibsed. The OHT date was obtained from the University of
ennsylvania’s transplant database.
This analysis of clinical VO2 studies was approved by the
niversity of Pennsylvania’s Institutional Review Board.
ardiopulmonary exercise testing. All patients underwent
ymptom-limited cardiopulmonary exercise testing using a
amped treadmill protocol with breath-by-breath expired
as analysis using a computerized metabolic cart (Sensor-
edics Vmax 29, Yorba Linda, California). Three different
rotocols were used for testing based on the patient’s
elf-reported symptom class, as has been published else-
here (19). Studies were interpreted by a single reader
A. K.). The anaerobic threshold was determined by the
-slope method (20).
tatistical analysis. Kaplan-Meier analyses were used to
ssess survival. Data from different patient populations were
ompared using log-rank testing. We stratified patients
ccording to the Weber classification (class A: peak VO2
20 ml/kg/min; class B: peak VO216 to 20 ml/kg/min;
lass C: peak VO2 10 to 16 ml/kg/min; class D: peak
O2 10 ml/kg/min) to determine whether Weber classes
re predictive of survival in each gender (21). To determine
cut-off peak VO2 value when cardiac transplantation would
ersus Women
Men, n (%)
(n  427)
Women, n (%)
(n  167) p Value
53  12 49  11 0.0002
25  11 29  13 0.001
29  5 29  7 NS
0.05
338 (79) 115 (69)
78 (18) 49 (29)
5 (1) 2 (1)
6 (1) 1 (1)
0.001
206 (48) 113 (68)
181 (43) 25 (15)
21 (5) 7 (4)
19 (4) 22 (13)
311 (73) 120 (72) NS
332 (78) 123 (74) NS
61 (14) 36 (22) 0.05
184 (43) 57 (34) 0.05
22 (5) 13 (8) NS
306 (72) 115 (69) NS
300 (70) 124 (74) NS
40 (9) 20 (12) NS
135 (32) 36 (22) 0.03
45 (11) 8 (5) 0.05
68 (16) 9 (5) 0.0006
150 (35) 45 (27) NS
111 (26) 26 (16) 0.01
28 (7) 13 (8) NS
63 (15) 5 (3) 0.001
.en V
)
 0.05
receptor blockers; COPD  chronic obstructive pulmonary
rillator; LVEF  left ventricular ejection fraction.
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June 6, 2006:2237–42 Effects of Gender on Peak VO2e appropriate, linear regression analysis was used, plotting
urvival against peak VO2. The peak VO2 value correspond-
ng to an 85% one-year transplant-free survival was then
etermined. All analyses were performed using SAS soft-
are version 8 (SAS Institute Inc., Cary, North Carolina).
ESULTS
atient population. Of the 726 patients reviewed, 594
atients met our inclusion criteria, of whom 427 (72%) were
en and 167 (28%) were women. The etiology of HF was
schemic in 206 patients (35%) and non-ischemic in 388
65%); 431 (73%) patients were receiving beta-blockers, 455
77%) an angiotensin-converting enzyme inhibitor, and 97
16%) an angiotensin II receptor blocker.
A higher percentage of women than men were black
29% vs. 18%, p  0.05) (Table 1). On average, women
ere younger than men (mean age 49  11 years vs. 53 
2 years, p  0.0002) and had a higher LVEF (29  13%
s. 25  11%; p  0.001). The etiology of HF was
ignificantly different between the genders, with 15% of
omen and 43% of men having an ischemic cardiomyopa-
igure 1. Patient survival across genders. Kaplan-Meier curves comparing
Table 2. Exercise Parameters
Study P
Baseline VO2 (ml/kg/min) 2.8 
Peak VO2 (ml/kg/min) 15.9 
Resting HR (beats/min) 77 
Peak HR (beats/min) 132 
Resting SBP (mm Hg) 112 
Peak SBP (mm Hg) 139 
Resting DBP (mm Hg) 71 
Peak DBP (mm Hg) 77 
Peak RER 1.09 
Number reaching AT, n (%) 449
Perceived exertion at peak (Borg scale) 17.5 
Plus-minus values are mean  standard deviation. NS  p
AT  anaerobic threshold; DBP  diastolic blood press
systolic blood pressure; VO2  oxygen consumption.urvival in male and female heart failure patients. Using a log-rank test, the
ifference between the curves is significant with p  0.0001.
%hy (p  0.001). This may explain the lower percentage of
omen on aspirin (34% vs. 43%, p  0.05), lipid lowering
edications (22% vs. 32%, p  0.03), and nitrates (5% vs.
1%, p  0.05).
ardiopulmonary exercise test results. The mean peak
O2 in our study group was 15.9  6.7 ml/kg/min (Table
), with a peak respiratory exchange ratio (RER) of 1.09 
.11. As shown in Table 2, women had a lower peak VO2
han men (14.0 4.9 ml/kg/min vs. 16.6 7.1 ml/kg/min;
 0.0001) (Fig. 1). A lower percentage of women reached
naerobic threshold than men (66% vs. 79%; p 0.01), and
eak RER was lower in women (1.05  0.10 vs. 1.11 
.11; p  0.0001). However, the peak Borg Scale of
erceived Exertion was similar between genders (17.7 2.2
s 17.4  2.0, p  NS). Linear regression analysis con-
rmed that the observed differences in peak VO2 were
ndependent of race, LVEF, body mass index, HF etiology,
eta-blocker use, RER, and history of hypertension, diabe-
es, atrial fibrillation, and lung disease. Stratified analysis by
chievement of anaerobic threshold did not alter the results.
urvival data. During the study period, 69 patients died
nd 70 received an OHT. The median transplant-free
urvival was 18.4 months, with an 85% one-year transplant-
ree survival (Table 3). Survival was significantly different
etween men and women in our population (Fig. 1).
omen were found to have a median transplant-free
urvival of 22.2 months and a 94% one-year transplant-free
urvival, whereas men had a median survival of 17.4 months
nd an 81% one-year transplant-free survival (Table 3).
Furthermore, when stratifying patients using the Weber
lassification (21), we found that Weber class accurately
redicted survival in the entire study group (Fig. 2), as well
s in each gender (Fig. 3). However, Weber class had less
redictive power in women than men because women in
tion Men Women p Value
2.8  0.4 2.6  0.4 0.0001
16.6  7.1 14.0  4.9 0.0001
76  14 80  15 0.002
130  29 135  25 0.04
113  18 109  16 0.03
140  28 136  26 NS
71  11 70  11 NS
77  13 76  14 NS
1 1.11  0.11 1.05  0.10 0.0001
338 (79%) 111 (66%) 0.01
17.4  2.0 17.7  2.2 NS
.
R  heart rate; RER  respiratory exchange ratio; SBP 
able 3. Patient Population Outcomes
Overall Men Women
eaths 69 55 14
ransplants 70 61 9
eaths and transplants 139 116 23opula
0.4
6.7
14
28
18
28
11
14
0.1
(76%)
2.1
 0.051-yr transplant-free survival 85% 81% 94%
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Effects of Gender on Peak VO2 June 6, 2006:2237–42lass A, B, and C had similar survival (Fig. 3). As seen in
able 4, one-year transplant-free survival was significantly
orse in men than in women across all Weber classes (p 
.0001). Cox regression analyses confirmed that the ob-
erved protective effects of female gender on transplant-free
urvival persisted despite controlling for peak VO2, age, race,
eta-blocker use, HF etiology, RER, and history of hyper-
ension, diabetes, atrial fibrillation, and lung disease,
hereas younger age, higher peak VO2, higher LVEF,
emale gender, and history of hypertension were all protec-
ive. Taken together, these data suggest that at any peak
O2 value, women have a better survival than men.
Because more men achieved anaerobic threshold com-
ared with women, we repeated our analyses stratified by
igure 2. Weber class predicts patient survival. Kaplan-Meier curves
omparing survival in patients across Weber classes. Using a log-rank test,
he difference between the curves is significant with p  0.0001.
igure 3. Predictive value of Weber classes in men and women. Kaplan-M
cross Weber classes. Using a log-rank test, difference between curves is significhievement of anaerobic threshold. This did not alter the
esults, although the models including those who achieved
naerobic threshold or an RER 1.1 were more predictive.
Because one-year post-transplantation survival is 85%
United Network for Organ Sharing), we determined a
ut-off value of VO2, which corresponds to 85% one-year
urvival. Overall, a peak VO2 value of 11.2 ml/kg/min
orresponded to an 85% one-year survival, but this value was
ignificantly lower in women than in men (10.0 vs. 11.5
l/kg/min; p  0.001).
ISCUSSION
ver the last decade, peak VO2 has been an important
eterminant of the appropriate timing of cardiac transplan-
ation. In the landmark study by Mancini et al. (3), patients
ith a peak VO2 14 ml/kg/min were found to have a poor
rognosis and were deemed appropriate for cardiac trans-
lantation. The applicability of this cut off value for peak
O2 to the general population, however, has been called into
uestion because only 19 of 122 patients in the Mancini
tudy were women (3). To date, no study evaluating peak
O2 has included enough women to delineate the prognos-
ic value of peak VO2 in this population (5,6,8,9).
The natural history of HF is different in women and men.
n women, HF develops later in life, and is more often
ttributable to hypertension and less frequently to coronary
urves comparing survival in male (A) and female (B) heart failure patients
able 4. One-Year Transplant-Free Survival by Weber Class
Weber Class Overall (n) Men (n) Women (n)
A 96% (120) 95% (102) 99% (18)
B 91% (201) 90% (150) 95% (51)
C 83% (179) 77% (114) 95% (65)
D 70% (92) 59% (59) 84% (33)cant with p  0.0001.
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June 6, 2006:2237–42 Effects of Gender on Peak VO2isease (11–13). Additionally, women with non-ischemic
ardiomyopathy have better survival than men (11–15).
espite their improved survival, women with HF are more
ymptomatic and have more hospital admissions (13,16–
8,22). Given these gender-based differences in the patho-
hysiology and progression of HF and the relative paucity of
ata on cardiopulmonary exercise testing in women, we
escribe a large, diverse population of ambulatory HF
atients to help define the gender effects on functional
apacity in HF patients.
We found that women with HF have a lower peak VO2
han men, despite controlling for race, body mass index,
VEF, beta-blocker use, RER, achievement of anaerobic
hreshold, and HF etiology. This gender-based difference is
ell established in normal subjects and is thought to be
ttributable to smaller muscle mass, lower baseline meta-
olic rate, and lower hemoglobin levels in women
17,22,23). However, we found that despite their lower peak
O2 levels, women have longer survival times than men.
A number of previous studies have shown that women
ith HF have better survival than men (3,11,14,15). The
urrent study confirms such observations despite a lower
eak VO2 in women and confirms the finding by Aaronson
nd Mancini (9) that the prognostic value of peak VO2 is less
ccurate in women. Here, women of Weber functional
lasses A, B, and C have no significant difference in their
urvival. In contrast, men with HF had a gradual reduction
n survival with each increase in Weber class. These data
uggest a threshold in the progression of disease in women,
fter which survival decreases dramatically.
Given this survival pattern, we attempted to find the
oint at which one-year transplant-free survival in women
rops below 85%, corresponding to expected one-year
ost-transplantation survival. We found that women do not
each this point until their peak VO2 is below 10 ml/kg/min.
hus, it seems that female HF patients may not gain a
urvival advantage from cardiac transplantation until their
eak VO2 is 10 ml/kg/min, significantly lower than the
ore recently suggested 12 ml/kg/min in patients on
eta-blockers (7). On the other hand, men with a peak VO2
11.5 ml/kg/min have better survival than their post-
ransplantation counterparts, a value comparable to the 12
l/kg/min proposed by Peterson et al. (7).
tudy limitations. Our study is limited because it is a
etrospective analysis of a prospectively collected database.
onsequently, our results require confirmation by a pro-
pective, randomized clinical trial. Additionally, there were
number of differences in the baseline characteristics of the
ender groups studied here. Although these differences were
orrected statistically, it is not possible to control for all
ifferences, known or unknown, which could explain our
esults. Because such discrepancies likely reflect differences
n the pathophysiology of HF between men and women, we
nticipate that any study evaluating gender and HF will
ncounter similar limitations.Additionally, the observed discrepancy in peak VO2 be-
ween men and women may be seen if the groups are
resenting at different stages of HF. However, given that
omen in our study were younger, had a higher LVEF, and
ad better survival, yet lower peak VO2 values, this possi-
ility seems unlikely. Our database did not contain adequate
nformation on the number of patients with an intraventric-
lar conduction delay or those treated with cardiac resyn-
hronization therapy, both of which can affect peak VO2
24). Thus, our results could be explained by a dispropor-
ionate incidence of intraventricular conduction delay or
umber of biventricular pacemakers in one of the gender
roups. Moreover, it is important to note that serial cardio-
ulmonary exercise testing may add significant information
o a patient’s clinical evaluation, whereas this study evalu-
ted the use of a single cardiopulmonary exercise test.
astly, because recent findings have suggested a strong
rognostic value to the minute ventilation–carbon dioxide
roduction relationship (VE/VCO2 slope), future studies
hould evaluate whether this parameter may correct for the
bserved gender differences in HF patients (25).
onclusions. We found that women with HF have lower
eak VO2 values than men. Despite this, women with HF
ad better survival than men. These results suggest that
ifferent thresholds for peak VO2 by gender may be neces-
ary for heart transplantation timing. It seems that cardiac
ransplantation in the current era may be deferred in female
F patients until their peak VO2 is 10 ml/kg/min, as
pposed to 11.5 ml/kg/min in men. The current practice of
niformly applying peak VO2 as an aid for determining the
ptimal timing of cardiac transplantation should be
e-examined.
eprint requests and correspondence: Dr. Andrew Kao, Cardio-
ascular Consultants, PC, 4330 Wornall Road, Suite 2000, Kansas
ity, Missouri 64111. E-mail: akao@cc-pc.com.
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